A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Trametinib (Primary)
- Indications Juvenile myelomonocytic leukaemia
- Focus Therapeutic Use
- 11 Oct 2017 Status changed from not yet recruiting to recruiting.
- 05 Oct 2017 Planned initiation date changed from 30 Jun 2017 to 7 Oct 2017.
- 21 Jun 2017 New trial record